---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-076222"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:49:22.966430+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx stockholders approve amended 2023 incentive plan and elect directors at annual meeting

## Summary
- Class II directors Dunsire, Narachi, and Sanders elected with over 66M votes each for terms until 2027.
- Amended 2023 Incentive Plan approved: 51.9M for, 22.3M against; adds 8.5M shares plus prior plan rollover shares.
- Ernst & Young ratified as independent auditor for FY2024 with 77.2M votes for (98.2% of votes cast).
- Advisory vote on executive compensation passed with 54.8M for vs 19.3M against; 4.3M broker non-votes.

## SEC filing metadata
- accession: 0000950170-24-076222
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017024076222/0000950170-24-076222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017024076222/rare-20240618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-076222
- JSON: https://secwatch.observer/filing/0000950170-24-076222.json
- Plain text: https://secwatch.observer/filing/0000950170-24-076222.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.